The Global Obesity Management Market is expected to reach US$ 1.3 Bn by 2031

Obesity is a prominent community health problem in many parts of the world. It is associated with numerous health disorders including gallbladder disease, heart disease, diabetes, stroke, hypertension, and fatty liver disease in addition to some cancers. According to a recent Future Market Insights (FMI) report, the Obesity Management market is set to surpass US$ 1.2 Bn by the end of the forecast period in 2031, with a CAGR of over 5%.

Globally, more than 1 billion individuals are overweight or obese and the numbers continue rising. This high prevalence of obesity will drive demand for obesity management products and services in the long term.

According to the World Health Organization (WHO), approximately 1.9 billion adults were overweight and 650 million adults were obese. Whereas 38.3 million children under 5 years of age were either overweight or obese in 2019. One in three adults in North America is obese. In the U.S., 80 million adults and 12.7 million children suffer from obesity.

Furthermore, there has been an increase in the per capita healthcare expenditure, especially in developed countries, with better reimbursement policies. People are now inclined towards out-of-pocket expenditure healthcare. Personal health, grooming, and concerns over social discrimination are leading people to take obesity management consultations.

However, the unprecedented pandemic crisis has had a significant impact on the obesity management market due to a slump of patient footfall in hospitals and clinics. Preference is now being given to the treatment of COVID-19 patients, limiting resources for anti-obesity consultations and related drugs or surgeries.

Also, there has been a halt in clinical trials for weight management drugs. However, with the availability and commencement of the COVID-19 vaccination, the clinical trials are resuming and are anticipated to pick up pace during the forecast period. Also, the adoption of telehealth and in developing countries is likely to bode well for the future of the market in the long term.

Request For Sample Copy @ https://www.futuremarketinsights.com/reports/sample/rep-gb-587

Key Takeaways from Obesity Management Market Study

  • Bupropion and Naltrexone will reflect register faster growth at a CAGR of 8.4%, owing to an increase in the preference for combination therapy in weight management.
  • Gastric sleeve surgery will account for over 40% of the market throughout the forecast period owing to benefits of simplicity and time-efficiency.
  • The U.S. will lead the North America market with a share of over 64% in 2021, driven by continuing diet and lifestyle issues prevalent in the country.
  • Germany followed by Russia are leading markets in Europe, reflecting CAGR of over 6% through the end of 2031, driven by improvements in public health programs.
  • Japan dominates the East Asia market, accounting for 49% value share in 2021, with government awareness programs contributing to growth.

β€œThe rapidly increasing obesity cases and the resultant chronic diseases have triggered concern among patients and healthcare professionals. The COVI-19 crisis has alarmed people, as overweight people are at higher risk of acquiring SARS-COV2. This consciousness may help in encouraging obesity management uptake through 2021 and beyond,” says the FMI analyst.

Obesity Management Market

Key Participant Insights

Prominent players in the Obesity Management Market are focusing on collaborations, mergers & acquisitions for global expansion and enhanced opportunities focused on emerging economies thereby, enhancing their market presence.  

The key market players covered by FMI include GlaxoSmithKline Plc., VIVUS, Inc., Novo Nordisk A/S, Currax Pharmaceuticals LLC, Cheplapharm Arzneimittel GmbH, Bausch Health Companies Inc., and Takeda Pharmaceuticals, Inc.

Want more insights?

Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends on each of the sub-segments from 2016 to 2031. The global Obesity Management Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the Obesity Management Market based on drug type (Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide), surgery type (Gastric Bypass Surgery, Adjustable Gastric Banding Surgery, Gastric Sleeve Surgery, Duodenal Switch Surgery, and Others), and distribution channel (Hospitals Pharmacies, Retail Pharmacies, and E-commerce) across seven major regions.

Visit For Report TOC https://www.futuremarketinsights.com/reports/obesity-management-market/table-of-content

Key Questions Answered in the Report

  • How much is the obesity management market worth?

In the year 2021, the global obesity management market will reach US$ 788.6 Mn.

  • What will be the demand outlook of obesity management?

According to FMI analysis the obesity management market will surpass US$ 1.2 Bn in 2031.

  • What was the last 5 year CAGR for the obesity management market?

Between 2016 and 2020, the obesity management market grew at a CAGR of 4.10%.

  • What is the share of top 5 players in the obesity management market?

GlaxoSmithKline Plc., VIVUS, Inc., Novo Nordisk A/S, Currax Pharmaceuticals LLC, and Cheplapharm Arzneimittel GmbH account for 89.5% of the market.

  • What are the top 5 countries driving demand in the obesity management market?

The U.S., Australia, India, GCC countries, and Japan are leading countries driving demand for obesity management.

  • What is the North America obesity management market outlook?

North America will account for more than 32% of the global market in 2021, and is expected to hold 34.8% in 2031.

Leave a comment

Your email address will not be published. Required fields are marked *